According to Stirling Products, the company is in discussions with several major pharmaceutical companies about partnerships on products using its patented high density aerosol (HDA) device. The company says that its ultrasound-based HDA technology produces a concentration level three times higher than that of other ultrasonic devices. One version of the device has 510(k) approval, and Stirling says that it is developing more advanced versions. Read the company’s press release.
Stirling talking to potential partners for HDA device
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
